1. Roivant Sciences achieved a 44% stock return over two years but underperformed the S&P 500; 2. The author maintains a 'Hold' rating, balancing optimism for pipeline catalysts with concerns about valuation and execution risks; 3. While strategic partnerships and clinical progress offer upside, competitive pressures and unproven commercialization remain key challenges.